Combination Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloproliferative Disorders

DISEASE CHARACTERISTICS:

Idiopathic myelofibrosis (IMF) with at least 1 poor prognosis characteristic, including but not limited to:

Hemoglobin less than 10 g/dL
Platelet count less than 100,000/mm^3
Hepatomegaly (i.e., palpable liver edge 5 cm below costal margin)
Clinical requirement for splenectomy
Other myeloproliferative disorders in an IMF like myelofibrotic state eligible

No evidence of leukemic progression, e.g.:

Greater than 15% peripheral blood blasts
Fever or bone pain of unknown origin
Rapidly progressing splenomegaly

No other causes for myelofibrosis, such as:

Collagen vascular disorder
Lymphoma
Granulomatous infection
Metastatic carcinoma
Hairy cell leukemia
Myelodysplastic syndrome
No active central nervous system disease

One of the following donor/patient pairings is required:

Donor status:

Genotypic or phenotypic HLA-matched relative

Maximum patient age of 65

One antigen HLA-mismatched relative, HLA-matched unrelated donor, or one antigen HLA-mismatched unrelated donor

Maximum patient age of 55
Transplant on this protocol allowed for patients registered on protocol FHCRC-1106.00

PATIENT CHARACTERISTICS:

Age:

65 and under

Performance status:

Not specified

Hematopoietic:

See Disease Characteristics

Hepatic:

Bilirubin no greater than 2 times normal
SGPT no greater than 4 times normal

Renal:

Creatinine no greater than two times normal OR
Creatinine clearance at least 50%

Cardiovascular:

Ejection fraction at least 50%
Cardiac evaluation required if signs or symptoms of coronary artery disease or congestive heart failure

Other:

HIV negative
No active infection
Patients excluded from this protocol are referred to protocol FHCRC-179.05

PRIOR CONCURRENT THERAPY:

Biologic therapy:

Not specified

Chemotherapy:

Not specified

Endocrine therapy:

Not specified

Radiotherapy:

Not specified

Surgery:

Not specified